Menopozda Düşük Doz Estrojen ve SNRI Kullanımı

Östrojen terapisinin menopozda sıcak basmaları ve gece terlemeleri için etkinliği tartışılmaz olmasına rağmen var olan riskleri nedeniyle tercih nedeni olmayabiliyor. JAMA Internal Medicine dergisinin son sayısında Harvard Tıp Fakültesinde psikiyatri profesörü olan Hadine Joffe ve arkadaşlarının düşük doz estrojen ve SNRI grubundan venlefaksinin menopozal vazomotor semptomları üzerine etkilerine dair makalesi yayınlandı. Makalenin özetini ilginize sunuyoruz.  – TürkPsikiyatri 

menopoz_belirtileri

Low-Dose Estradiol and the Serotonin-NorepinephrineReuptake Inhibitor Venlafaxine for Vasomotor SymptomsA Randomized Clinical Trial

Hadine Joffe, MD, MSc1,2,3; Katherine A. Guthrie, PhD4; Andrea Z. LaCroix, PhD4; Susan D. Reed, MD, MPH5; Kristine E. Ensrud, MD, MPH6,7; JoAnn E. Manson, MD, DrPH1; Katherine M. Newton, PhD8; Ellen W. Freeman, PhD9,10; Garnet L. Anderson, PhD4; Joseph C. Larson, MS4; Julie Hunt, PhD4; Jan Shifren, MD3; Kathryn M. Rexrode, MD, MPH1; Bette Caan, DrPH11; Barbara Sternfeld, PhD11; Janet S. Carpenter, PhD, RN12; Lee Cohen, MD3

AMA Intern Med. 2014;174(7):1058-1066. 


Importance  Estrogen therapy is the gold standard treatment for hot flashes and night sweats, but some women are unable or unwilling to use it because of associated risks. The serotonin-norepinephrine reuptake inhibitor venlafaxine hydrochloride is used widely as a nonhormonal treatment. While the clinical impression is that serotonin-norepinephrine reuptake inhibitors are less effective than estrogen, these medications have not been simultaneously evaluated in one clinical trial to date.

Objective  To determine the efficacy and tolerability of low-dose oral 17β-estradiol and low-dose venlafaxine extended release in alleviating vasomotor symptoms (VMS).

Design, Setting, and Participants  In total, 339 perimenopausal and postmenopausal women with at least 2 bothersome VMS per day (mean, 8.1 per day) were recruited from the community to MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) clinical network sites between December 5, 2011, and October 15, 2012.

Interventions  Participants were randomized to double-blind treatment with low-dose oral 17β-estradiol (0.5 mg/d) (n = 97), low-dose venlafaxine hydrochloride extended release (75 mg/d) (n = 96), or placebo (n = 146) for 8 weeks.

Main Outcomes and Measures  The primary outcome was the mean daily frequency of VMS after 8 weeks of treatment. Secondary outcomes were VMS severity, bother, and interference with daily life. Intent-to-treat analyses compared the change in VMS frequency between each active intervention and placebo and between the 2 active treatments.

Results  Compared with baseline, the mean VMS frequency at week 8 decreased to 3.9 (95% CI, 2.9-4.9) VMS per day (52.9% reduction) in the estradiol group, to 4.4 (95% CI, 3.5-5.3) VMS per day (47.6% reduction) in the venlafaxine group, and to 5.5 (95% CI, 4.7-6.3) VMS per day (28.6% reduction) in the placebo group. Estradiol reduced the frequency of symptoms by 2.3 more per day than placebo (P < .001), and venlafaxine reduced the frequency of symptoms by 1.8 more per day than placebo (P = .005). The results were consistent for VMS severity, bother, and interference. Low-dose estradiol reduced the frequency of symptoms by 0.6 more per day than venlafaxine (P = .09). Treatment satisfaction was highest (70.3%) for estradiol (P < .001 vs placebo), lowest (38.4%) for placebo, and intermediate (51.1%) for venlafaxine (P = .06 vs placebo). Both interventions were well tolerated.

Conclusions and Relevance  Low-dose oral estradiol and venlafaxine are effective treatments for VMS in women during midlife. While the efficacy of low-dose estradiol may be slightly superior to that of venlafaxine, the difference is small and of uncertain clinical relevance.

Link: www.archinte.jamanetwork.com/article.aspx?articleid=1876676

 

Bir Cevap Yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir